ARTICLE
6 March 2024

What's Up With U.S. Merger Remedies?

AV
Axinn Veltrop & Harkrider

Contributor

Incisive. Inclusive. Invested. We’re Axinn.

Experienced, tenacious, and always trial-ready, we are committed to understanding complex legal challenges that impact the future of our clients’ businesses, globally.

Focusing on antitrust, intellectual property, and high-stakes litigation, our extensive teams in the U.S. possess deep knowledge and client-side experience across a range of sectors, including technology, healthcare, life sciences, and consumer products.

With a strong culture of diversity, equity, and inclusion, we build relationships with our clients and colleagues alike, helping communities and acting with purpose. Our client service, entrepreneurialism, and inquisitive nature sit at the heart of the firm, enabling us to prioritize client goals and achieve successful outcomes.

Axinn managing partner Jeny Maier co-hosted ABA's Our Curious Amalgam podcast in an episode entitled, "What's Up With U.S. Merger Remedies?"
United States Antitrust/Competition Law
ABA Our Curious Amalgam

Axinn managing partner Jeny Maier co-hosted ABA's Our Curious Amalgam podcast in an episode entitled, "What's Up With U.S. Merger Remedies?"

Jeny spoke with Dan Ducore, former Assistant Director of the Federal Trade Commission's Bureau of Competition Compliance Division, to discuss the growing skepticism towards merger remedies by the U.S. antitrust authorities.

Click here to access the episode.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More